3m Innovative Properties Company

Biothera Inc.

Coley Pharmaceutical Group, Inc.

Hibercell, Inc.

Biothera Pharmaceuticals, Inc.

Michael E Danielson

Tushar A Kshirsagar

Philip D Heppner

David S Hays

Shri Niwas

Nandita Bose

Mary A Antonysamy

George W Griesgraber

Bryon A Merrill

John F Gerster

Maureen Ann Kavanagh

Sarah A Strong

Joshua R Wurst

Richard M Walsh

Michael J Rice

William H Moser

Sarah J Slania

William J Grossman

Kyle S Michel

Matthew R Radmer

Ryan B Prince

Jason D Bonk

Joan T Moseman

Gregory D Lundquist, Jr

Keith B Gorden

Mariana I Nelson

Kyle J Lindstrom

Chad A Haraldson

Azim Alan Celebi

Peter Maimonis

William Bedingham

Ranjani V Parthasarathy

David T Amos

Gregory J Marszalek

Scott E Langer

Karl J Manske

John P Vasilakos

Anissa S H Chan

Donald J Cox

Steven M Leonardo

Sarah C Slania

John C Faletti

Sarah Johannessen

David J Squire

This disclosure describes, in one aspect, a method for identifying β-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble β-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble β-glucan to bind to the immune cells, and detecting soluble β-glucan hound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of β-glucan, and co-administering to the subject a soluble β-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.

Methods for identifying beta-glucan binding to immune cells

This disclosure describes, in one aspect, a method for identifying &#x3b2;-glucan binding to immune cells of a subject. Generally, the method includes obtaining a blood sample from the subject, the blood sample comprising immune cells, adding soluble &#x3b2;-glucan to at least a portion of the blood sample and incubating the mixture under conditions allowing the soluble &#x3b2;-glucan to bind to the immune cells, and detecting soluble &#x3b2;-glucan bound to the immune cells. In another aspect, this disclosure describes a method that generally includes identifying the subject as a low binder of &#x3b2;-glucan, and co-administering to the subject a soluble &#x3b2;-glucan and an antibody preparation capable of converting the subject from a low binder to a high binder.

The present invention relates to yeast cell wall 5 compositions enriched with mannose, mannose extracts and processes for making the same.

Yeast cell wall enriched in mannan oligosaccharide protein

This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to &#x3b2;-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-&#x3b2;-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-&#x3b2;-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-&#x3b2;-glucan antibody.

Beta-glucan assay methods

This disclosure describes, in one aspect, a composition that includes a &#x3b2;-glucan component and an antibody component that specifically binds to the &#x3b2;-glucan. In another aspect, this disclosure describes a method of increasing a subject's response to &#x3b2;-glucan immunotherapy. Generally, the method includes identifying the subject as a low binder of &#x3b2;-glucan and administering to the subject a composition that comprises a &#x3b2;-glucan moiety conjugated to the therapeutic antibody. In some cases, the therapeutic antibody can be an anti-tumor antibody.

Compositions and methods for beta-glucan immunotherapy

Described herein are beta-glucan compounds, compositions, and methods. Generally, the methods exploit the observation that beta-glucan compounds can bind to B cells. Thus, the methods generally include administering a beta-glucan compound to a subject in an amount effective for the beta-glucan compound to bind to a B cell and modulate at least one biological function of the B cell.

Beta-glucan compounds, compositions, and methods

&#x3b2;-glucan assay methods

Pyrazolopyridin-4-amines, pyrazoloquinolin-4-amines, pyrazolonaphthyridin-4-amines, 6,7,8,9-tetrahydropyrazoloquinolin-4-amines, and prodrugs thereof, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Pyrazolopyridines and analogs thereof

A method of preferentially inducing IFN-&#x3b1; biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-&#x3b1; biosynthesis in an animal are disclosed.

Method of preferentially inducing the biosynthesis of interferon

Methods of providing at least one reagent for use in a device for processing sample material, delivering at least one reagent to a device for processing sample material, and adding at least one reagent to at least one of the steps in a process for detecting or assaying a nucleic acid; a support film coated with a dry reagent layer; and a device for processing sample material having a support film coated with a dry reagent layer contained within at least one chamber of the device are disclosed.

Supported reagents, methods, and devices

Fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a &#x2014;CH(&#x2014;X&#x2014;R)&#x2014; group in the fused ring at the 1-position of the imidazo ring, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Chiral fused [1,2]imidazo[4,5-c] ring compounds

Substituted fused [1,2]imidazo[4,5-c] ring compounds (e.g., imidazo[4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridines) with a &#x2014;CH(&#x2014;R)&#x2014; group in the fused ring at the 1-position of the imidazo ring, wherein Rincludes a functional group, for example, an amide, sulfonamide, urea, carbamate, ester, ketone, ether, a thio analog of the forgoing, sulfone, oxime, or hydroxylamine, pharmaceutical compositions containing the compounds, intermediates, methods of making the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds

Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, and an aryl or heteroaryl substituent at the 7-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-&#x3b1; biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Hydroxyalkyl substituted imidazoquinoline compounds and methods

Pyrazolo[3,4-c]quinolines, pyrazolo[4,5-c]naphthyridines, and analogs thereof, eg., 6,7,8,9-tetrahydro pyrazolo[3,4-c]quinolines, and, pharmaceutical compositions containing the compounds, intermediates, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inhibiting cytokine biosynthesis in animals and in the therapeutic or prophylactic treatment of diseases by inhibiting cytokine biosynthesis are disclosed.

Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods

[object Object]

Growing community of inventors

Saint Paul, MN, United States of America

Michael E Danielson